CRA-CRC training can rebuild sponsor-site trust that remote monitoring weakened. Find out what a 2026 study found and how clinical teams can act on it.
Remote monitoring has cut the face time between sponsors and trial sites, and communication has suffered. A new study from Japan tests whether reciprocal CRA-CRC training can repair that link.
Its findings suggest that one shared day can reshape how sponsor and site teams work together for months.
Image
Why Does Sponsor-Site Distance Matter So Much Now?
Clinical research associates (CRAs) work for sponsors or contract research organisations (CROs). Clinical research coordinators (CRCs) work at the trial site. Together, they form the main communication channel for every protocol in the field.
The two roles live in different worlds. CRAs operate in metrics-driven corporate settings, while CRCs mainly work inside hospitals, where participant care comes first. That gap can create mismatched expectations and slow responses.
Remote and risk-based monitoring have only widened the gap. Sponsors now run many selection and initiation visits remotely, and remote monitoring has matured since the COVID-2019 pandemic.
A Tufts CSDD survey found that sites often report poor communication and too little respect from sponsors. Fewer visits mean fewer chances to learn how the other side works.
Site staff also juggle many sponsors, each with its own systems and timelines. Poor mutual understanding turns routine requests into friction. Friction delays start-up, enrolment, and data cleaning.
Hosono and colleagues tested a practical fix in a study published in February 2026. They asked whether structured, face-to-face exchange can restore understanding between CRAs and CRCs.
The findings emphasise that efficiency gains from remote oversight may quietly erode the relationships that keep trials moving.
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
How Does Reciprocal CRA-CRC Training Work?
The Japanese research team ran the programme between November 2023 and July 2024.
Participation was voluntary, and a confidentiality agreement covered the visits between Teikyo University Hospital, Bristol-Myers Squibb K.K., and the University of Tokyo.
Each visit ended with a joint discussion between CRAs and CRCs.
The hospital day for sponsor staff
The sponsor sent 17 employees, including 11 CRAs, to the hospital for about eight hours. They joined three smaller cohorts.
Experienced CRCs led a simulation of a first investigational drug visit, using the process sheets the site writes for each trial.
The hospital tour then followed the participant path.
It covered a dermatology clinic, an inpatient ward, the pharmacy, the central laboratory, and the clinical trials centre.
Staff also explained contract negotiation and institutional review board (IRB) procedures.
Sponsor staff met no trial participants.
The sponsor day for site staff
The hospital sent 14 staff, including 11 CRCs, to the sponsor office for about four hours.
They toured the workspace, the remote source data verification room, and the document archive.
Sponsor teams then demonstrated their clinical trial management system, electronic trial master file, and electronic data capture tools.
Presenters also covered query handling, serious adverse event reporting, and CRO oversight. Live questions were welcome throughout.
For most coordinators, it was their first look inside a sponsor.
Image
What Did the CRO-CRA Data and Participants Reveal?
The researchers tested the training on three fronts.
Surveys captured how well participants understood the other side, and how they felt about it, before and after the visits. Open-ended answers showed what people actually learned.
A six-month follow-up then asked whether daily work habits had changed.
Together, these sources show effects on knowledge, attitudes, and behaviour.
Understanding rose sharply
CRO-CRA Participants rated their own understanding of the other side on five-point scales, before training and within a week afterwards.
Scores rose on most items in both groups, and the authors report statistically significant changes. Examples include:
CRAs lifted their median score for understanding routine hospital care processes from two to four, and for overall CRC workflow from three to five.
CRCs lifted their median score for sponsor organisational structure and the monitoring process from two to four.
Even items with high starting scores, such as the value of the other role, shifted slightly. The authors read that as growing confidence.
Impressions shifted too
Sponsor staff came to see site hospitals as more welcoming and less intimidating. Their median rating for a bright and welcoming atmosphere rose from three to five.
On the other side, site staff found sponsor communication easier, with a median moving from 2.5 to four.
Not everything moved. CRCs still saw sponsor staff as very busy and sponsor coordination as difficult, showing that understanding softens attitudes but it does not remove structural complexity.
What participants said they learned
Text-mining of the free-text answers produced eight themes grouped them into four lessons: Each side’s workflows, who to contact for what, the other side’s priorities, and how to share information.
CRAs realised how hard it is to run participant visits without errors in a busy hospital, while CRCs saw how many steps sit behind protocol development, which explained why sponsors push for fast start-up.
Several CRAs admitted they had expected site staff to be intimidating, and found the reality more relaxed.
Two traits emerged that were not part of the formal curriculum: Intellectual humility and mutual respect. The authors link these to a Delphi-based set of team science competencies for clinical research professionals.
Behaviour change after six months
Follow-up responses came from 12 of the 17 CRAs and nine of the 14 CRCs.
During study start-up, 70% of CRA respondents and 88% of CRC respondents reported changes in how they work. During trial conduct, 67% of CRAs and all nine responding CRCs did the same.
The changes were practical.
CRAs now picture how participants and coordinators move through a site when they review processes and CRCs now try to resolve data capture queries themselves before escalating, and say resolution times have fallen.
They also explain why enrolment stalls, not only whether eligible participants exist.
Limitations for clinical teams
The CRO-CRC evidence is encouraging but narrow. It covers one sponsor, one university hospital, and small cohorts of volunteers.
All outcomes were self-reported, and the authors did not measure query turnaround, protocol deviations, or staff turnover, as such it may not be the best indicator of performance in clinical development.
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.
Image
Turning Shared Understanding Into Clinical Trial Performance
The CRO-CRC study does not prove that training improves trial metrics but it does show a short, low-cost, and repeatable way to build sponsor-site relationships. Teams can act on it now.
Practical steps for sponsors, CROs, and sites
Make it reciprocal. Send sponsor staff to sites and site staff to sponsors. One-way tours miss half the gap.
Bring in CROs. Many monitoring relationships run through vendors, so strong CRO oversight needs the same shared exposure.
Show the systems. Let site teams see how trial management, master file, and data capture tools shape sponsor requests.
Measure results. Track query resolution time, start-up duration, and protocol deviation rates before and after each exchange.
Link it to monitoring strategy. Pair visits with risk-based monitoring plans under ICH E6(R3), so less on-site contact does not mean weaker relationships.
A caution applies. Training will not fix poor processes or unrealistic timelines.
In fact it works best when sponsors also act on what site teams then ask for, such as clearer query guidance and earlier notice of deadlines.
Sponsor-Site and CRA-CRC Relationships Determine Clinical Trial Success
CRA-CRC training offers a practical response to the communication gap that remote monitoring and decentralisation of clinical trials has widened.
A short, reciprocal exchange can improve mutual understanding, soften perceptions, and change daily practice for most Clinical Development teams.
Sponsors should pilot it, measure objective outcomes, and share the results.
At Pharmatica, we focus on the Operational and Clinical Development decisions that determine whether trials deliver on time. Our Insights connect evidence, Regulation, and site realities, so executives can act with confidence.
Pharmatica: Insight. Connection. Impact.
Image
Frequently Asked Questions
What is reciprocal CRA-CRC training?
Reciprocal CRA-CRC training is a short exchange in which sponsor staff visit a clinical trial site, and site staff visit the sponsor. Each side observes the other’s daily work, hears explanations from experienced colleagues, and joins a shared discussion afterwards.
Why do CRAs and CRCs sometimes struggle to communicate?
CRAs work within corporate, metrics-driven sponsor environments, while CRCs work within participant-focused hospitals. Different priorities, systems, and timelines create misaligned expectations. Reduced site visits under remote and risk-based monitoring leave fewer chances to bridge that gap.
Does CRC-CRA training change how teams work?
Most respondents said yes. Of those engaged in a small trial in Japan, 70% of CRAs and 88% of CRCs reported changed behaviour during study start-up and up to 6 months later. During trial conduct, 67% of CRAs and all responding CRCs reported changes. These figures are self-reported.
Can remote monitoring harm sponsor-site relationships?
Remote monitoring is efficient, but it reduces direct contact. That contact helps teams learn each other’s priorities. Remote models need deliberate relationship-building, such as reciprocal visits, shared workflow maps, and clear escalation routes.
Can sponsors apply CRC-CRA training at scale?
Probably, with care. The 2026 Japanese study covered one sponsor, one hospital, and small voluntary groups. Sponsors should pilot the model across several sites, include CROs, and track objective measures such as query resolution time and clinical trial start-up duration.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
0
Why not support
Nicole Dale
by giving this content a like
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
Learn how drug discovery scientists are evolving alongside AI, computational biology, and multidisciplinary research to accelerate therapeutic innovation.
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Comments (0)